Drug-class evidence

Liraglutide clinical trials

2 pivotal trials of liraglutide, spanning Saxenda. 4,153 total participants across the published evidence base.

What we know about liraglutide

Liraglutide is a once-daily GLP-1 receptor agonist marketed as Saxenda for chronic weight management at the 3.0mg dose. The SCALE program established efficacy across obesity, obesity with type 2 diabetes, sleep apnea, and weight-loss maintenance settings, with mean weight loss of approximately 5-8% in the pivotal trials.

Percent weight loss across Liraglutide obesity trials

Primary-endpoint percent body-weight change for the published liraglutide weight-management trials. Conducted on FDA-approved branded products only.

Effect sizes across liraglutide trials

Trial	Brand	Indication	Weight loss	A1C reduction	N · year
SCALE Obesity and Prediabetes	Saxenda	Obesity / overweight	8.0%	—	3,731 · 2015
SCALE Maintenance	Saxenda	Obesity / overweight	6.2%	—	422 · 2013

All liraglutide trials

Trials cited are for the FDA-approved branded products containing liraglutide. Compounded versions have not been studied in equivalent randomized controlled trials. GLP1Zoom does not provide medical advice; discuss treatment with your prescribing clinician. Full disclaimer.